Appriss Health is paying a reported $500m to buy healthcare collaboration platform developer PatientPing, allowing Alphabet's GV to exit.

SBI Investment will help manage the drug distributor’s Medipal Innovation Fund, which will invest in entrepreneurs in areas such as drug discovery and healthcare.

The health data analytics provider's series E round was co-led by Kaiser Permanente Group Trust at a $1bn valuation and also featured McKesson Ventures.

Lundbeckfonden Ventures and Chiesi Ventures have once again invested in the ocular oncology therapy developer, which has now raised $191m in total.

The firm specialises in setting up spinouts out of universities and corporations, and now has more than $1.6bn in assets under management.

XtalPi and Astellas Venture Management contributed to a $45.6m round that took the drug discovery technology provider's total funding to over $60m.

Parkwalk Advisors has returned to back a $46m round for PhoreMost, weeks after the latter’s spinout Neophore attracted $21m in a series B.

Providence's health capacity management system has been spun off with $20m from investors including Providence Ventures and Kaiser Permanente Ventures

The McKesson-backed healthcare analytics software provider boosted its valuation to $3.3bn in a series E round that came just two months after its series D.

Novo and Lundbeck are in line for exits from the mitochondrial disease therapy developer, which has raised $145m across two funding rounds.